Bonferoni Maria Cristina, Caramella Carla, Catenacci Laura, Conti Bice, Dorati Rossella, Ferrari Franca, Genta Ida, Modena Tiziana, Perteghella Sara, Rossi Silvia, Sandri Giuseppina, Sorrenti Milena, Torre Maria Luisa, Tripodo Giuseppe
Department of Drug Sciences, University of Pavia, V.le Taramelli 12, 27100 Pavia, Italy.
Pharmaceutics. 2021 Aug 26;13(9):1341. doi: 10.3390/pharmaceutics13091341.
Tissue repair and regeneration is an interdisciplinary field focusing on developing bioactive substitutes aimed at restoring pristine functions of damaged, diseased tissues. Biomaterials, intended as those materials compatible with living tissues after in vivo administration, play a pivotal role in this area and they have been successfully studied and developed for several years. Namely, the researches focus on improving bio-inert biomaterials that well integrate in living tissues with no or minimal tissue response, or bioactive materials that influence biological response, stimulating new tissue re-growth. This review aims to gather and introduce, in the context of Italian scientific community, cutting-edge advancements in biomaterial science applied to tissue repair and regeneration. After introducing tissue repair and regeneration, the review focuses on biodegradable and biocompatible biomaterials such as collagen, polysaccharides, silk proteins, polyesters and their derivatives, characterized by the most promising outputs in biomedical science. Attention is pointed out also to those biomaterials exerting peculiar activities, e.g., antibacterial. The regulatory frame applied to pre-clinical and early clinical studies is also outlined by distinguishing between Advanced Therapy Medicinal Products and Medical Devices.
组织修复与再生是一个跨学科领域,专注于开发生物活性替代物,旨在恢复受损、患病组织的原始功能。生物材料是指体内给药后与活组织相容的材料,在这一领域发挥着关键作用,并且已经成功研究和开发了数年。具体而言,研究重点在于改进生物惰性生物材料,使其能很好地融入活组织且组织反应极小或无反应,或者改进能影响生物反应、刺激新组织再生的生物活性材料。本综述旨在为意大利科学界收集并介绍应用于组织修复与再生的生物材料科学的前沿进展。在介绍组织修复与再生之后,综述重点关注可生物降解和生物相容的生物材料,如胶原蛋白、多糖、丝蛋白、聚酯及其衍生物,这些材料在生物医学科学领域有着最具前景的成果。同时也关注那些具有特殊活性(如抗菌)的生物材料。还通过区分高级治疗用医药产品和医疗器械,概述了应用于临床前和早期临床研究的监管框架。